Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Research Article

The Value of Thioredoxin Level and its Gene Polymorphism in the Diagnosis of Post- HCV Hepatocellular Carcinoma

Author(s): Hatem Samir Alegaily, Moataz Yousry Soliman, Ahmed Mehrez Gad, Eid Abdel-Monsef Abou-Omar, Mohamed Saleh, Raghda Samir Abdellatif, Amina Fouad, Omar Mahmoud Azzam, Sherief Abd-Elsalam* and Yousry Esam-Eldin Abo-Amer

Volume 19, Issue 1, 2023

Published on: 26 December, 2022

Page: [67 - 73] Pages: 7

DOI: 10.2174/1573394718666220829122410

Price: $65

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies and a leading cause of cancer-related death worldwide. Indeed, we need a novel tumor marker other than AFP for early detection and to improve the outcome. Serum thioredoxin is a promising protein involved in the pathogenesis of many malignancies. The study aims to evaluate serum thioredoxin and its gene polymorphism in HCC in cirrhotic patients due to HCV infection.

Patients and Methods: 350 patients with HCC, 350 patients with chronic liver diseases, and 300 healthy controls were enrolled in our study. Serum thioredoxin level was measured by ELISA, and molecular study of thioredoxin domain-containing 5 (TXNDC5) gene polymorphism (rs1225943) polymorphism using real-time polymerase chain reaction by Taqman allele discrimination was done for all subjects.

Results: Our study revealed a significant increase in serum thioredoxin levels in patients with HCC compared to chronic liver diseases and healthy controls. Using the Receiver operating characteristic (ROC) curve at the area under the curve (AUC) 0.917 and a cut-off value of > 14.6 U/ml, our overall sensitivity and specificity for the HCC group over the other groups were 86 % and 92.15%, respectively with 92.2% positive predictive value and 54.9% negative predictive value. The molecular study of TXNDC5 gene polymorphism (rs1225943) polymorphism revealed no significant difference between the studied groups.

Conclusion: Serum thioredoxin may be used as a promising tumor marker for HCC. Future research is needed to assess its use as a single or combined with other markers in the diagnosis and follow-up of the patients after interventions.

Keywords: Liver cirrhosis, hepatocellular carcinoma, biomarker, tumor marker, thioredoxin, polymorphism.

[1]
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021; 7(1): 6.
[http://dx.doi.org/10.1038/s41572-020-00240-3] [PMID: 33479224]
[2]
Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Canc Inst 2020; 32(1): 5.
[http://dx.doi.org/10.1186/s43046-020-0016-x] [PMID: 32372179]
[3]
Wege H, Li J, Ittrich H. Treatment lines in hepatocellular carcinoma. Visc Med 2019; 35(4): 266-72.
[http://dx.doi.org/10.1159/000501749] [PMID: 31602390]
[4]
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16(10): 589-604.
[http://dx.doi.org/10.1038/s41575-019-0186-y] [PMID: 31439937]
[5]
Cui K, Ou Y, Shen Y, Li S, Sun Z. Clinical value of circulating tumor cells for the diagnosis and prognosis of Hepatocellular Carcinoma (HCC). Medicine 2020; 99(40): e22242.
[http://dx.doi.org/10.1097/MD.0000000000022242] [PMID: 33019399]
[6]
Luo P, Wu S, Yu Y, et al. Current status and perspective biomarkers in AFP negative HCC: Towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res 2020; 26(2): 599-603.
[http://dx.doi.org/10.1007/s12253-019-00585-5] [PMID: 30661224]
[7]
Chang TS, Wu YC, Tung SY, et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol 2015; 110(6): 836-44.
[http://dx.doi.org/10.1038/ajg.2015.100] [PMID: 25869392]
[8]
Mohammadi F, Soltani A, Ghahremanloo A, Javid H, Hashemy SI. The thioredoxin system and cancer therapy: A review. Cancer Chemother Pharmacol 2019; 84(5): 925-35.
[http://dx.doi.org/10.1007/s00280-019-03912-4] [PMID: 31367788]
[9]
Zhang J, Li X, Han X, Liu R, Fang J. Targeting the thioredoxin system for cancer therapy. Trends Pharmacol Sci 2017; 38(9): 794-808.
[http://dx.doi.org/10.1016/j.tips.2017.06.001] [PMID: 28648527]
[10]
Li J, Cheng ZJ, Liu Y, et al. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget 2015; 6(11): 9551-63.
[http://dx.doi.org/10.18632/oncotarget.3314] [PMID: 25871387]
[11]
Chawsheen HA, Ying Q, Jiang H, Wei Q. A critical role of the Thioredoxin Domain Containing Protein 5 (TXNDC5) in redox homeostasis and cancer development. Genes Dis 2018; 5(4): 312-22.
[http://dx.doi.org/10.1016/j.gendis.2018.09.003] [PMID: 30591932]
[12]
Mohamed AA, Abdel-Rahman AAH, Saad S, et al. HLA-DQ gene polymorphisms associated with hepatitis B virus in patients with hepatocellular carcinoma progression. Curr Cancer Ther Rev 2021; 17(1): 75-81.
[http://dx.doi.org/10.2174/1573394716666200712151208]
[13]
Mohammed MA, Shabana H, Sheta T, Omar NM, Mohammed SA. Vitamin D receptor gene polymorphisms as a predictive risk factor for hepatocellular carcinoma development and severity in chronic hepatitis B. Int J Cancer Res 2016; 13(1): 26-35.
[http://dx.doi.org/10.3923/ijcr.2017.26.35]
[14]
Zinkin NT, Grall F, Bhaskar K, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008; 14(2): 470-7.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-0586] [PMID: 18223221]
[15]
Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: A large-scale, multicentre study. Lancet Oncol 2012; 13(8): 817-26.
[http://dx.doi.org/10.1016/S1470-2045(12)70233-4] [PMID: 22738799]
[16]
Kondo N, Nakamura H, Masutani H, Yodoi J. Redox regulation of human thioredoxin network. Antioxid Redox Signal 2006; 8(9-10): 1881-90.
[http://dx.doi.org/10.1089/ars.2006.8.1881] [PMID: 16987040]
[17]
Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein Thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002; 62(17): 5089-95.
[PMID: 12208766]
[18]
Raffel J, Bhattacharyya AK, Gallegos A, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003; 142(1): 46-51.
[http://dx.doi.org/10.1016/S0022-2143(03)00068-4] [PMID: 12878985]
[19]
Sheta T, Selim M, Sabry M, Saed A. Serum thioredoxin as a diagnostic marker for hepatocellular carcinoma in Cirrhotic hepatitis C patients. Med J Viral Hepat 2021; 5(2): 9-15.
[http://dx.doi.org/10.21608/mjvh.2021.158271]
[20]
Nassar A, El-Rauf A, Mohammed S, Mostafa A. Evaluation of serum level of thioredoxin and its gene polymorphism in diagnosis of hepatocellular carcinoma of HCV-infected patients. Benha Med J 2020; 37: 111-30.
[21]
Tamai T, Uto H, Takami Y, et al. Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma. World J Gastroenterol 2011; 17(44): 4890-8.
[http://dx.doi.org/10.3748/wjg.v17.i44.4890] [PMID: 22171130]
[22]
Omran MM, Farid K, Omar MA, Emran TM, El-Taweel FM, Tabll AA. A combination of α-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. Ann Hepatol 2020; 19(2): 179-85.
[http://dx.doi.org/10.1016/j.aohep.2019.09.002] [PMID: 31648804]
[23]
Park MS, Kim SK, Shin HP, Lee SM, Chung JH. TXNDC5 gene polymorphism contributes to increased risk of hepatocellular carcinoma in the Korean male population. Anticancer Res 2013; 33(9): 3983-7.
[PMID: 24023338]
[24]
Wu X, Wang Q, Lu Y, Zhang J, Yin H, Yi Y. Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Sci Rep 2021; 11(1): 6069.
[http://dx.doi.org/10.1038/s41598-021-85688-3] [PMID: 33727662]
[25]
Negm O, Abou Saif S, El Gharib M, Yousef M, Abd-Elsalam S. Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2017; 29(3): 317-21.
[http://dx.doi.org/10.1097/MEG.0000000000000790] [PMID: 27893491]
[26]
Watany M, Badawi R, Elkhalawany W, Abd-Elsalam S. Study of Dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J Clin Diagn Res 2017; 11(2): OC32-4.
[http://dx.doi.org/10.7860/JCDR/2017/23095.9450] [PMID: 28384913]
[27]
Abdelfattah AAM, Rizk F, Hawash N, Hanafy A, El-kalla F, Abd-Elsalam S. Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions in the liver. Int J Hyperthermia 2018; 34(8): 1367-71.
[http://dx.doi.org/10.1080/02656736.2018.1424946] [PMID: 29308685]
[28]
El-Gebaly F, Abou-saif S, Elkadeem M, et al. Study of serum soluble programmed death ligand 1 as a prognostic factor in hepatocellular carcinoma in Egyptian patients. Curr Cancer Drug Targets 2019; 19(11): 896-905.
[http://dx.doi.org/10.2174/1568009619666190718141647] [PMID: 31538897]
[29]
Abdel GMT, Morad MA, El-Zamarany EA, et al. Autologous dendritic cells pulsed with lysate from an allogeneic hepatic cancer cell line as a treatment for patients with advanced hepatocellular carcinoma: A pilot study. Int Immunopharmacol 2020; 82: 106375.
[http://dx.doi.org/10.1016/j.intimp.2020.106375] [PMID: 32169808]
[30]
Elhendawy M, Abdul-Baki EA, Abd-Elsalam S, et al. MicroRNA signature in hepatocellular carcinoma patients: Identification of potential markers. Mol Biol Rep 2020; 47(7): 4945-53.
[http://dx.doi.org/10.1007/s11033-020-05521-4] [PMID: 32430845]

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy